Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States.

JAMA · 2020

Where this comes from

Abstract

This pharmacoepidemiology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends to evaluate whether recalls of ARBs prompted by discovery of potentially carcinogenic impurities shifted utilization of ARBs individually and as a drug class.